Please login to the form below

Inlyta

This page shows the latest Inlyta news and features for those working in and with pharma, biotech and healthcare.

MSD’s Keytruda catches up in kidney cancer

Combination therapy approved in EU for all risk groups. MSD’s Keytruda in combination with Inlyta (axitinib) has won European Commission (EC) approval in the first-line treatment of the most

Latest news

Keytruda scores in neoadjuvant triple negative breast cancer combo

Meanwhile, Keytruda is continuing to advance in other indications. In Europe, the Committee for Medicinal Products for Human Use (CHMP) has recommended Keytruda in combination with Inlyta (axitinib) as a
CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

Merck picked up another positive opinion for Keytruda, this time for use alongside Pfizer’s targeted cancer drug Inlyta (axitinib) for first-line treatment of renal cell carcinoma, and Bristol-Myers
Merck bulks up in cancer with $2.2bn Peloton buy

Keytruda is already making waves in RCC, having been approved for first-line RCC alongside Pfizer’s Inlyta (axitinib) in April.
Keytruda monotherapy fails in triple negative breast cancer

It added another new indication in April when it gained FDA approval in combination with Pfizer’s Inlyta for kidney cancer patients.
Merck claims key FDA okay for Bavencio in kidney cancer

The FDA has just approved Pfizer-partnered Bavencio (avelumab) in combination with Pfizer’s Inlyta (axitinib) as a first-line therapy for patients with advanced renal cell carcinoma (RCC), the most ... However it was pipped to the post in that

More from news
Approximately 6 fully matching, plus 27 partially matching documents found.

Latest Intelligence

The handover: Pfizer reshapes itself for a new era

The therapy area is dominated by Merck’s Keytruda, BMS’ Opdivo and Roche’s Tecentriq, but Pfizer is hoping that combinations such as its own Inlyta and Bavencio can help it ... The JAVELIN Renal 101 trial combining Bavencio with Inlyta in
Cancer immunotherapy: What's on the horizon?

They include Pfizer’s OX40 agonist PF-04518600, in early-stage testing in combination with the company’s Bavencio (avelumab) and targeted cancer drug Inlyta (axitinib) as well as chemotherapy,

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

Mirna hires former Pfizer director as CMO

Mirna will be banking on Dr Kim's extensive experience in oncology, which includes serving as global clinical lead for kidney cancer drugs Inlyta (axitinib) and Torisel (temsirolimus) during his time

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

A stumble, but not a fall – what’s next for Opdivo?

Back then, the UK’s cost-effectiveness watchdog NICE deemed Opdivo too pricey for renal cell carcinoma when taking into account the availability of Pfizer's Inlyta at a markedly lower
Oncology drugs under AMNOG

A benefit was found for Inlyta compared with Nexavar in the cytokine treatment group, on the basis of increased tolerability. ... of benefit in one category for these patients was enough to send Inlyta to negotiations for pricing.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.